BioSpace News Archive

GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the initiation of its Alamance study, a multi-center bladder cancer study conducted in collaboration with investigators at Memorial Sloan Kettering Cancer Center and the University of Wisconsin – Madison Carbone Cancer Center.

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization, announced the launch of its BravoAAV and ProntoLVV viral vector platforms.

Nectin Therapeutics, a biotechnology company developing novel targeted immunotherapies to address tumor immune resistance, and the Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation’s (MMRF) venture philanthropy subsidiary, today announced that the MIF has invested in Nectin Therapeutics to explore the potential of NTX1088.

Alcami Corporation, a leading contract development and manufacturing organization, announced the appointment of Laurent Boer to the newly created position of General Manager, Biostorage and Pharma Services.

Cardio Diagnostics Holdings, Inc, an artificial intelligence-powered precision cardiovascular medicine company, announced the introduction of the Actionable Clinical IntelligenceTM platform to expand the information available to clinicians prescribing the Epi+Gen CHD and PrecisionCHD laboratory developed tests.

Inspira™ Technologies OXY B.H.N. Ltd. has announced it will reveal the new ALICE™ device at the world’s largest Extracorporeal Life Support Organization conference, the 34th Annual ELSO Conference in Seattle, Washington, which will be held between the 28th of September and the 1st of October 2023.

Fzata, Inc. will be showcased at upcoming conferences for the ongoing Series A raise supporting the first-in-class Bioengineered Probiotic Yeast Medicines modality.

Celmatix Inc the leading women’s health biotech focused uniquely on ovarian biology, today announced that Dr. Susan Herbert has joined the company’s board of advisors.

Break Through Cancer is announcing the launch of the Targeting Clonal Hematopoiesis to Prevent AML TeamLab and the Eradicating Minimal Residual Disease in AML TeamLab.

Upkara announced that it has secured $9 million in Series A funding, including additional investment from prominent businessman and philanthropist, Bill Parfet, along with industry veteran, Paul Meister, former Chairman of Thermo Fisher Scientific.